Jesse C Nussbaum (Jesse Nussbaum)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Atrial Fibrillation

Top Venues

Journal of clinical pharmacology

CPT: pharmacometrics & systems pharmacology

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Jesse C Nussbaum, Azher Hussain, Peter Butera, Anthony P Ford, Michael M Kitt, Edward A O'Neill, Steven Smith, Gabriel Vargas, Terry O'Reilly, Chris Wynne, S Aubrey Stoch, Marian Iwamoto
Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults. Journal of clinical pharmacology 64 (8) (2024)
Jesse C Nussbaum, Azher Hussain, Peter Butera, Anthony P Ford, Michael M Kitt, Edward A O'Neill, Steven Smith, Gabriel Vargas, Terry O'Reilly, Chris Wynne, S Aubrey Stoch, Marian Iwamoto
Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults. Journal of clinical pharmacology (2024)
Akshita Chawla, Anna Largajolli, Azher Hussain, Huub Kleijn, Sihem Ait-Oudhia, Judith Anton, Hari Ananthula, Jesse C Nussbaum, Carmen La Rosa, Ferdous Gheyas
Population Pharmacokinetic Analysis of the P2X3-Receptor Antagonist Gefapixant. CPT: pharmacometrics & systems pharmacology (2023)
Geoffrey A Walford, An Bautmans, Carol Cannon, Kelly E Duncan, Kathleen Deschamps, Randolph P Matthews, Jesse C Nussbaum, S Aubrey Stoch
Considerations for Cell and Gene Therapy Programs Entering the Clinical Space. Clinical pharmacology and therapeutics (2023)
Jesse C Nussbaum, Azher Hussain, K Chris Min, Thomas C Marbury, Kenneth Lasseter, S Aubrey Stoch, Marian Iwamoto
Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist. Journal of clinical pharmacology 62 (11) (2022)
Jesse C Nussbaum, Azher Hussain, Anthony Ford, Peter Butera, Michael Kitt, Steve Smith, Aubrey Stoch, Marian Iwamoto
A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults. Lung 200 (3) (2022)
Jesse C Nussbaum, Azher Hussain, Bennett Ma, K Chris Min, Qing Chen, Charles Tomek, Marian Iwamoto, S Aubrey Stoch
Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans. Pharmacology research & perspectives 10 (1) (2022)